Publications:

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.

Npj Breast Cancer

Barroso-Sousa, Romualdo R; Keenan, Tanya E TE; Li, Tianyu T; Tayob, Nabihah N; Trippa, Lorenzo L; Pastorello, Ricardo G RG; Richardson Iii, Edward T ET; Dillon, Deborah D; Amoozgar, Zohreh Z; Overmoyer, Beth B; Schnitt, Stuart J SJ; Winer, Eric P EP; Mittendorf, Elizabeth A EA; Van Allen, Eliezer E; Duda, Dan G DG; Tolaney, Sara M SM

Publication Date: 2021-08-25

Variant appearance in text: KIT: L184L

PubMed Link: 34433812

Variant Present in the following documents:

• 41523_2021_287_MOESM1_ESM.xlsx, sheet 6

View BVdb publication page

mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis.

Cell Reports

Triki, Mouna M; Rinaldi, Gianmarco G; Planque, Melanie M; Broekaert, Dorien D; Winkelkotte, Alina M AM; Maier, Carina R CR; Janaki Raman, Sudha S; Vandekeere, Anke A; Van Elsen, Joke J; Orth, Martin F MF; Grünewald, Thomas G P TGP; Schulze, Almut A; Fendt, Sarah-Maria SM

Publication Date: 2020-06-23

Variant appearance in text: KIT: L184L

PubMed Link: 32579932

Variant Present in the following documents:

• mmc5.xlsx, sheet 3

View BVdb publication page

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Oncotarget

Siegel, Matthew B MB; Liu, Selina Qiuying SQ; Davare, Monika A MA; Spurgeon, Stephen E SE; Loriaux, Marc M MM; Druker, Brian J BJ; Scott, Emma C EC; Tyner, Jeffrey W JW

Publication Date: 2015-08-07

Variant appearance in text: KIT: L184=

PubMed Link: 26254279

Variant Present in the following documents:

• oncotarget-06-18921-s001.pdf

View BVdb publication page